UNICA IRIS Institutional Research Information System

CARTA, MANOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 190.217
NA - Nord America 6.758
AS - Asia 2.916
SA - Sud America 403
AF - Africa 70
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 1
Totale 200.373
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 188.579
US - Stati Uniti d'America 6.657
SG - Singapore 1.182
CN - Cina 956
UA - Ucraina 373
SE - Svezia 337
BR - Brasile 321
DE - Germania 290
VN - Vietnam 264
FI - Finlandia 168
GB - Regno Unito 152
FR - Francia 139
HK - Hong Kong 104
KR - Corea 87
IN - India 82
CA - Canada 56
NL - Olanda 40
IQ - Iraq 35
AR - Argentina 34
RU - Federazione Russa 30
BD - Bangladesh 28
ES - Italia 27
JP - Giappone 27
MX - Messico 22
TR - Turchia 19
ID - Indonesia 17
PK - Pakistan 16
ZA - Sudafrica 16
BE - Belgio 15
SA - Arabia Saudita 15
VE - Venezuela 14
PH - Filippine 13
PL - Polonia 13
CZ - Repubblica Ceca 12
CO - Colombia 11
AT - Austria 10
EG - Egitto 10
MA - Marocco 10
AE - Emirati Arabi Uniti 9
KE - Kenya 9
JO - Giordania 6
PY - Paraguay 6
TH - Thailandia 6
TW - Taiwan 6
AZ - Azerbaigian 5
CL - Cile 5
MY - Malesia 5
NZ - Nuova Zelanda 5
PE - Perù 5
PS - Palestinian Territory 5
RO - Romania 5
TN - Tunisia 5
UZ - Uzbekistan 5
EC - Ecuador 4
IE - Irlanda 4
JM - Giamaica 4
LB - Libano 4
LT - Lituania 4
NP - Nepal 4
AO - Angola 3
AU - Australia 3
BB - Barbados 3
DZ - Algeria 3
PA - Panama 3
SN - Senegal 3
BG - Bulgaria 2
BO - Bolivia 2
CH - Svizzera 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HN - Honduras 2
HU - Ungheria 2
IR - Iran 2
KG - Kirghizistan 2
KZ - Kazakistan 2
MN - Mongolia 2
NG - Nigeria 2
NI - Nicaragua 2
NO - Norvegia 2
SK - Slovacchia (Repubblica Slovacca) 2
TT - Trinidad e Tobago 2
BH - Bahrain 1
BJ - Benin 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
ET - Etiopia 1
EU - Europa 1
GD - Grenada 1
GM - Gambi 1
KH - Cambogia 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
MT - Malta 1
Totale 200.366
Salva come PNG Salva come JPEG
Città #
Cagliari 176.889
Uta 11.295
Fairfield 721
Ashburn 625
Singapore 607
Woodbridge 554
Chandler 411
Houston 380
San Jose 368
Ann Arbor 306
Boardman 259
Seattle 244
Wilmington 241
Cambridge 233
Dallas 216
Nyköping 201
Beijing 199
Jacksonville 199
Dearborn 121
Los Angeles 109
Council Bluffs 107
Santa Clara 104
Helsinki 96
Hong Kong 95
The Dalles 93
Ho Chi Minh City 90
Hefei 86
Seoul 86
Nanjing 79
Shanghai 79
New York 72
Lauterbourg 71
Hanoi 56
Boston 48
San Diego 45
Milan 39
Buffalo 37
Munich 35
Guangzhou 28
Frankfurt am Main 24
Redwood City 24
Tokyo 24
Orem 23
Phoenix 22
São Paulo 21
Falls Church 20
Rome 20
Shenyang 20
Tianjin 19
Washington 19
Dong Ket 18
London 18
Norwalk 18
Redondo Beach 18
Montreal 17
Toronto 17
Baghdad 15
Hebei 15
Nuremberg 15
Stockholm 15
Chennai 14
Mountain View 14
Verona 14
Brussels 13
Changsha 13
Sassari 13
Amsterdam 12
Brooklyn 12
Chicago 12
Da Nang 12
Denver 12
Düsseldorf 12
Jiaxing 12
Orange 12
San Francisco 12
Atlanta 11
Padova 11
Turku 11
Brno 10
Hangzhou 10
Mumbai 10
Pisa 10
Dhaka 9
Haiphong 9
Nanchang 9
Pune 9
Zhengzhou 9
Manchester 8
Porto Alegre 8
Riyadh 8
San Mateo 8
Columbus 7
Hải Dương 7
Johannesburg 7
Nairobi 7
New Delhi 7
Newark 7
Rio de Janeiro 7
Taizhou 7
Warsaw 7
Totale 196.328
Salva come PNG Salva come JPEG
Nome #
Efficacy and safety of the 5-Hydroxytryptophan on Levodopa-Induced Motor Complications in Parkinson's disease 24.356
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease 7.302
5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction 5.827
Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats 4.635
Higher free d-aspartate and N-methyl-d-aspartate levels prevent striatal depotentiation and anticipate 1-DOPA-induced dyskinesia 4.535
Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. 4.337
Pathophysiology of L-dopa-induced motor and non-motor complications in Parkinson's disease 4.296
The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease 4.082
Chronic tryptophan deprivation attenuates gating deficits induced by 5-HT 1A, but not 5-HT 2 receptor activation 3.734
Could the serotonin theory give rise to a treatment for levodopa-induced dyskinesia in Parkinson's disease? 3.734
Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia 3.694
Effect of selective and non-selective serotonin receptor activation on l-DOPA-induced therapeutic efficacy and dyskinesia in parkinsonian rats 3.582
Antidyskinetic effect of A2A and 5HT1A/1B receptor ligands in two animal models of Parkinson's disease 3.551
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation 3.468
Essential fatty acids deficient diet modulates N-Acylethanolamide profile in rat's tissues 3.413
Tryptophan-deficient diet increases the neurochemical and behavioral response to amphetamine 3.377
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Parkinson's disease: a preliminary finding 3.346
Vitamin A deficiency produces spatial learning and memory impairment in rats 3.267
null 2.940
Vitamin A deficiency induces motor impairments and striatal cholinergic dysfunction in rats 2.874
VGF peptides as novel biomarkers in Parkinson’s disease 2.775
Biphasic effects of ethanol on acetylcholine release in the rat prefrontal cortex 2.681
Amphetamine usage, misuse, and addiction processes: an overview 2.648
Augmented cocaine-induced accumbal dopamine efflux, motor activity and place preference in rats fed with a tryptophan-deficient diet 2.630
Study of the antidyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia 2.588
Pregnenolone for the treatment of L-DOPA-induced dyskinesia in Parkinson's disease 2.576
The serotonergic system in levodopa-induced dyskinesia 2.566
Optimization of continuous in vivo DOPA production and studies of ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats 2.380
Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding 2.368
Startle Reflex as a possible biomarker associated with REM sleep behavior disorders in the prodromal stage of Parkinson's disease 2.347
Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration 2.300
null 2.298
Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA-induced dyskinesia in a rat model of Parkinson's disease 2.270
Efficacy and Safety of the 5-Hydroxytryptophan on REM Sleep Behavior Disorder in Parkinson's Disease 2.269
Modulation of the Startle Response in REM Sleep Behavior Disorder 2.263
5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: From animal models to clinical investigation 2.249
null 2.247
Foetal cell transplantation for Parkinson's disease: focus on graft-induced dyskinesia 2.196
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations 2.178
Role of serotonin neurons in L-DOPA- and graft-induced dyskinesia in a rat model of parkinson's disease 2.175
Efficacy and safety of the 5-Hydroxytryptophan on Depression and Apathy in Idiopathic Parkinson's disease 2.166
Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: A correlation study 2.164
The levels of the NMDA receptor co-agonist D-serine are reduced in the substantia nigra of MPTP-lesioned macaques and in the cerebrospinal fluid of Parkinson’s disease patients 2.020
On the Effect of Eltoprazine in Dyskinetic Hemiparkinsonian Rats 1.936
Contribution of pre-synaptic mechanisms to l-DOPA-induced dyskinesia 1.790
L-DOPA and serotonergic neurons: functional implication and therapeutic perspectives in Parkinson's disease 1.771
null 1.663
null 1.607
null 1.604
Serotonin neuron-dependent and -independent reduction of dyskinesia by 5-HT1A and5-HT1B receptor agonists in the rat Parkinson model 1.552
null 1.471
Dyskinesia in Parkinson’s disease: a clinical complication and an open scientific question 1.431
BDNF Overexpression Increases Striatal D3Receptor Level at Striatal Neurons and Exacerbates D1-Receptor Agonist-Induced Dyskinesia 1.412
Role of serotonin neurons in the induction of L-DOPA- and graft-induced dyskinesias in Parkinson´s disease 1.401
Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease 1.270
Transcriptome analysis in a rat model of L-dopa-induced dyskinesia 1.256
Nurr1 is Required for Maintenance of Maturing and Adult Midbrain Dopamine Neurons 1.252
A simple method for large-scale generation of dopamine neurons from human embryonic stem cells 1.251
Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update 1.217
Role of aberrant striatal dopamine D1 receptor/cAMP/protein kinase A/DARPP32 signaling in the paradoxical calming effect of amphetamine 1.117
A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease 1.110
The GTP-binding protein Rhes modulates dopamine signalling in striatal medium spiny neurons 1.092
Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease 1.092
Modulation of serotonergic transmission by eltoprazine in L-DOPA-induced dyskinesia: Behavioral, molecular, and synaptic mechanisms 1.090
Vitamin A deficiency affects neither frontocortical acetylcholine nor working memory 979
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia 961
Involvement of the serotonin system in L-DOPA-induced dyskinesias 954
Effects of tryptophan deficiency on prepulse inhibition of the acoustic startle in rats 938
Critical involvement of cAMP/DARPP-32 and ERK signaling in L-DOPA-induced dyskinesia 910
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson’s disease 842
Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease 837
Altered dopaminergic innervation and amphetamine response in adult Otx2 conditional mutant miceAberrant accumbal innervation and sensitized motor response to amphetamine in Otx2 conditional mutant mice 832
null 780
Pharmacological validation of a mouse model of L-dopa-induced dyskinesia 754
Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression 747
Transplantation of human embryonic stem cell-derived cells to a rat model of Parkinson’s disease: effect of in vitro differentiation on graft survival and teratoma formation 721
BDNF over-expression induces striatal serotonin fiber sprouting and increases the susceptibility to L-DOPA-induced dyskinesia in 6-OHDA-lesioned rats 702
Nusinersen Induces Disease-Severity-Specific Neurometabolic Effects in Spinal Muscular Atrophy 683
The serotonergic system in L-DOPA-induced dyskinesia: pre-clinical evidence and clinical perspective 620
null 565
Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degeneration 535
null 475
SMN deficiency perturbs monoamine neurotransmitter metabolism in spinal muscular atrophy 440
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats 427
Homeostasis of serine enantiomers is disrupted in the post-mortem caudate putamen and cerebrospinal fluid of living Parkinson's disease patients 378
Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia 333
null 320
Expanding the therapeutic potential of neuro(active)steroids: a promising strategy for hyperdopaminergic behavioral phenotypes 259
Effect of 5-alpha reductase inhibitors in animal models of Parkinson’s disease 205
Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease 190
The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease 117
Early Dopaminergic Dysfunction Induces PRO-VGF Changes in Blood and Brain of Rats with Alpha-Synuclein Overexpression 86
VGF INVOLVEMENT ON PARKINSON’S DISEASE 26
Totale 200.705
Salva come PNG Salva come JPEG
Categoria #
all - tutte 236.907
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 236.907
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.044 0 0 0 0 0 0 0 0 0 0 0 1.044
2021/20227.370 719 760 434 332 526 628 560 320 524 804 895 868
2022/202311.709 921 1.307 1.260 1.031 1.015 1.085 600 957 847 907 1.217 562
2023/202412.241 416 406 378 630 1.108 1.739 1.846 1.090 483 861 1.329 1.955
2024/202578.427 28.618 18.312 23.829 2.498 1.247 1.314 1.564 121 289 202 172 261
2025/20266.423 427 204 558 543 521 468 1.675 358 426 553 453 237
Totale 200.705